Addition of insulin to oral therapy in patients with type 2 diabetes

American Journal of the Medical Sciences

Volumn 331, Issue 5, 2006, Pages 257-263

  Nelson, Scott E ^a   Palumbo, Pasquale J ^b  

^a Bolivar Health and Rehabilitation Center and Cleveland Family Medicine   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Diabetes; Glycemic control; Hypoglycemia; Insulin; Oral diabetic agents

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN; BIGUANIDE DERIVATIVE; EXENDIN 4; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; CASE REPORT; COMORBIDITY; DRUG MIXTURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; UNITED STATES; WEIGHT GAIN;

EID: 33744498092     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200605000-00004     Document Type: Article

References (26)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
2. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28:S4-36.
3. Di Carli MF, Janisse J, Grunberger G, et al. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003;41:1387-93.
4. American College of Endocrinology. Consensus statement on guidelines for glycemic control. Endocr Pract 2002;8(Suppl 1):5-11.
5. Harris MI, Eastman RC, Cowie CC, et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999;22:403-8.
6. Garber AJ. Benefits of combination therapy of insulin and oral hypoglycemic agents. Arch Intern Med 2003;163:1781-2.
7. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12.
8. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003;289:2254-64.
9. Brandle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-4.
10. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.
11. Sherwin RS, Anderson RM, Buse JB, et al. Prevention or delay of type 2 diabetes. Diabetes Care 2004;27(Suppl 1): S47-54.
12. Edelman SV, Henry RR. Diagnosis and management of type 2 diabetes. Insulin therapy. 5th ed. Caddo (OK): Professional Communications; 2002. p. 121-48.
13. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6.
14. Kendall DA, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control of 3-0 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.
15. Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998;21:1052-7.
16. Fritsche A, Schmulling RM, Häring HU, et al. Intensive insulin therapy combined with metformin in obese type 2 diabetic patients. Acta Diabetol 2000;37:13-8.
17. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-32.
18. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-63.
19. Wright A, Burden AC, Paisey RB, et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6.
20. Janka HU, Plewe MD, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily pre-mixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2004;28:254-9.
21. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes. Diabetes Care 2005;28:260-5.
22. Ahmann AJ, Riddle MC. Insulin therapy in type 2 diabetes mellitus. In: Leahy JL, Cefalu WT, eds. Insulin therapy. New York: Marcel Dekker; 2002 p. 113-24.
23. Lantus [package insert]. Kansas City (MO): Aventis Pharmaceuticals; 2004.
24. Texas Diabetes Council. Insulin algorithm for type 2 diabetes mellitus in children and adults. 2004;45:11-647.
25. Henry RR, Gumbiner B, Ditzler T, et al. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993;16:21-31.
26. Leahy JL. Intensive insulin therapy in type 1 diabetes mellitus. In: Leahy JL, Cefalu WT, eds. Insulin therapy. New York: Marcel Dekker; 2002 p. 87-112.